Physician profile
Romin Bonakdar
NPI 1003236787
$3,325.75
in general payments reported to CMS, 2019-2025
23 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $102 · 2021: $396 · 2022: $590 · 2023: $745 · 2024: $750 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207 · Education: $30.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.00 |
| Education | $30.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $386.29 | 2020-2025 | Velphoro, Velphoro, Korsuva |
| Novartis Pharmaceuticals Corporation | $375.22 | 2024-2025 | |
| Glaxosmithkline, LLC. | $360.55 | 2021-2025 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $287.49 | 2020-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $225.24 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $224.13 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $201.75 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $171.28 | 2020-2023 | Acthar |
| Amgen INC. | $147.46 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $134.04 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $124.25 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $122.82 | 2021-2022 | |
| Genzyme Corporation | $114.27 | 2022-2023 | |
| Lilly USA, LLC | $83.63 | 2023-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.74 | 2023-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $56.02 | 2023 | Givlaari |
| Apellis Pharmaceuticals, INC. | $46.49 | 2025 | Empaveli |
| Ardelyx, INC. | $43.85 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $39.91 | 2022-2024 | Auryxia, Vafseo |
| Cycle Pharmaceuticals INC | $33.84 | 2025 | Venxxiva |
| Nxstage Medical, INC. | $33.84 | 2024 | |
| Opko Pharmaceuticals, LLC | $20.15 | 2021 | |
| Medtronic, INC. | $17.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romin Bonakdar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.